Medical micro- and nanomotors in the body.
Attributed to the miniaturized body size and active mobility, micro- and nanomotors (MNMs) have demonstrated tremendous potential for medical applications.
APA
Li H, Peng F, et al. (2023). Medical micro- and nanomotors in the body.. Acta pharmaceutica Sinica. B, 13(2), 517-541. https://doi.org/10.1016/j.apsb.2022.10.010
MLA
Li H, et al.. "Medical micro- and nanomotors in the body.." Acta pharmaceutica Sinica. B, vol. 13, no. 2, 2023, pp. 517-541.
PMID
36873176
Abstract
Attributed to the miniaturized body size and active mobility, micro- and nanomotors (MNMs) have demonstrated tremendous potential for medical applications. However, from bench to bedside, massive efforts are needed to address critical issues, such as cost-effective fabrication, on-demand integration of multiple functions, biocompatibility, biodegradability, controlled propulsion and navigation. Herein, we summarize the advances of biomedical MNMs reported in the past two decades, with particular emphasis on the design, fabrication, propulsion, navigation, and the abilities of biological barriers penetration, biosensing, diagnosis, minimally invasive surgery and targeted cargo delivery. Future perspectives and challenges are discussed as well. This review can lay the foundation for the future direction of medical MNMs, pushing one step forward on the road to achieving practical theranostics using MNMs.
같은 제1저자의 인용 많은 논문 (5)
- Epidemiological Analysis of Foodborne Botulism Outbreaks - China, 2004-2020.
- Comparison of efficacy of eight treatments for plantar fasciitis: A network meta-analysis.
- A Transformer-Based Deep Learning Model for predicting Early Recurrence in Hepatocellular Carcinoma After Hepatectomy Using Intravoxel Incoherent Motion Images.
- The multifaceted roles of the ACSL family in cancer: Metabolic reprogramming, ferroptosis regulation and tumour immune microenvironment remodelling.
- Neutrophil-inspired CRISPR/dCas9 nanomedicine to program self-destructing and bystander killing of tumor cell for selective cancer therapy.